Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calcium Dobesilate for COVID-19 Viral Load Reduction
NCT05305508Phase 2Completed
- Start
- May 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Calcium Dobesilate with Placebo (2 arms). Primary endpoint: SARS-CoV-2 Viral Load at Day 4. Started May 2022; status: completed.
02
Drugs
calcium dobesilate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05305508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05305508.